We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Merck splashes on Cubist, antibiotics prospects brighten.
- Authors
Morrison, Chris
- Abstract
The article reports on the acquisition of the firm Cubist Pharmaceuticals by the pharmaceutical firm Merck for 35 percent premium to the value of Cubist's shares over the previous five trading days. Topics discussed include impact of Merck-Cubist deal on the value of the biotechnology firm Cempra, views of Cempra's founder Prabhavathi Fernandes on the interest of Merck in the hospital market, and views of Jeffrey Wager, chairman at the biotechnology firm EnBiotix, on effect of deal.
- Subjects
CUBIST Pharmaceuticals Inc.; MERCK &; Co. Inc.; PHARMACEUTICAL industry mergers; FERNANDES, Prabhavathi; WAGER, Jeffrey
- Publication
Nature Biotechnology, 2015, Vol 33, Issue 2, p120
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0215-120